Israel VC Backs MiNA's Novel SaRNAs In Cancer, And Add-On Therapy Areas

Lead Compound Heading For Phase II

Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.    

RNA
Single Strand RNA • Source: Shutterstock

The UK start-up, MiNA Therapeutics, which is taking a novel approach to the development of RNA-targeted drugs by activating RNA rather han by the more conventional interference/inhibition, has raised $23m ($30m) in a series A financing led by Israel’s life sciences VC, aMoon. Existing investors also took part in the funding round. 

aMoon was co-founded in 2017 by Israeli billionaire Marius Nacht (a founder of the cyber security firm, Check Point Software...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.